Source-grounded facts extracted from Summit Therapeutics Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Summit Therapeutics Inc. shareholders approved Approval of an amendment to the Summit Therapeutics Inc. 2020 Stock Incentive Plan to increase the number of shares of the Company's common stock issuable under the Plan by 8,000,000 shares at the 2026-06-10 meeting.
“Proposal 4 For Against Abstain Broker Non-Votes Approval of an amendment to the Plan to increase the number of shares of the Company's common stock issuable under the Plan by 8,000,000 shares 619,799,393 27,247,910 124,199 30,576,341”
Summit Therapeutics Inc. shareholders approved Non-binding advisory vote to approve the compensation paid to the Company's named executive officers at the 2026-06-10 meeting.
“Proposal 3 For Against Abstain Broker Non-Votes Non-binding advisory vote to approve the compensation of named executive officers 622,624,328 24,445,791 101,383 30,576,341”
Summit Therapeutics Inc. shareholders approved Ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-10 meeting.
“Proposal 2 For Against Abstain Broker Non-Votes Ratification of the appointment of PricewaterhouseCoopers LLP for the fiscal year ending December 31, 2026 677,302,337 85,284 360,222 —”
Summit Therapeutics Inc. shareholders approved Election of nine directors to serve until the Company's 2027 Annual Meeting of Stockholders and until their successors are duly elected and qualified at the 2026-06-10 meeting.
“Proposal 1 Election of Directors Director Nominees For Withheld Broker Non-Votes Robert W. Duggan 636,409,964 10,761,538 30,576,341 Mahkam Zanganeh 637,405,433 9,766,069 30,576,341 Manmeet Soni 636,690,652 10,480,850 30,576,341 Kenneth A. Clark 622,127,920 25,043,582 30,576,341 Robert Booth 646,257,923 913,579 30,576,341 Alessandra Cesano 646,263,718 907,784 30,576,341 Yu (Michelle) Xia 636,028,876 11,142,626 30,576,341 Mostafa Ronaghi 646,570,238 601,264 30,576,341 Jeff Huber 646,659,701 511,801 30,576,341”
Summit Therapeutics Inc. reported financial results for the first quarter ended March 31, 2026.
“On April 30, 2026, Summit Therapeutics Inc. (the “Company”) issued a press release announcing its financial results and operational progress for the first quarter ended March 31, 2026.”
Summit Therapeutics Inc. issued 26,682,846 shares of common stock to multiple leading biotech institutional and individual accredited investors for $18.74 per Share.
“On October 21, 2025, Summit Therapeutics Inc. (the “Company”) entered into securities purchase agreements (the “Purchase Agreements”) with multiple leading biotech institutional and individual accredited investors (the “Investors”), for the sale by the Company in a private placement (the “Private Placement”) of an aggregate of 26,682,846 shares (the “Shares”) of the Company’s common stock, par value $0.01 per share (the “Common Stock”), at purchase price of $18.74 per Share, which was the closing price of the Common Stock on October 21, 2025, for aggregate gross proceeds to the Company of approximately $500.0 million.”
Ujwala Mahatme resigned as Director at Summit Therapeutics Inc..
“Effective June 12, 2024, Ujwala Mahatme informed Summit Therapeutics Inc. (the “Company”) that she was resigning from her role as a member of the Board of Directors (the “Board”) of the Company, and from each committee of the Board, to focus on her increasing professional commitments outside the Company.”
Summit Therapeutics Inc. entered into Distribution Agreement with J.P. Morgan Securities LLC valued at up to $90,000,000 (effective 2024-05-13).
“On May 13, 2024, Summit Therapeutics Inc. (the “Company”) entered into a distribution agreement (the “Distribution Agreement”) with J.P. Morgan Securities LLC (“Sales Agent”), as sales agent, pursuant to which the Company may offer and sell, from time to time, through the Sales Agent, shares of the Company’s common stock, par value $0.01 per share, having an aggregate offering price of up to $90,000,000 (the “Shares”).”
Summit Therapeutics Inc. reported financial results for the first quarter ended March 31, 2024.
“On May 1, 2024, Summit Therapeutics Inc. (the “Company”) issued a press release announcing its financial results and operational progress for the first quarter ended March 31, 2024.”
Mostafa Ronaghi was appointed as Director at Summit Therapeutics Inc..
“the board of directors (the “Board”) of Summit Therapeutics Inc. (the “Company”) unanimously approved the election of Mostafa Ronaghi, PhD, as a director of the Company and the appointment of Dr. Ronaghi to serve on the Compensation Committee of the Board.”
Bhaskar Anand was appointed as Chief Accounting Officer, Head of Finance at Summit Therapeutics Inc..
“On April 2, 2024, the Company hired Bhaskar Anand as Chief Accounting Officer, Head of Finance, to serve as its principal accounting officer.”
Manmeet Soni was appointed as Chief Financial Officer at Summit Therapeutics Inc..
“the Company appointed its Chief Operating Officer Manmeet Soni to the office of Chief Financial Officer, in which capacity he will serve as the Company’s principal financial officer, in addition to his continuing service as Chief Operating Officer.”
Ankur Dhingra resigned as Chief Financial Officer at Summit Therapeutics Inc..
“On April 2, 2024, Ankur Dhingra, the principal financial officer and principal accounting officer of Summit Therapeutics Inc. (the “Company”), resigned as Chief Financial Officer of the Company.”
Summit Therapeutics Inc. updated its the fourth quarter and year ended December 31, 2023 guidance (reaffirmed).
“On February 20, 2024, Summit Therapeutics Inc. (the “Company”) issued a press release announcing its financial results and operational progress for the fourth quarter and full year ended December 31, 2023.”
Summit Therapeutics Inc. reported financial results for the third quarter and nine months ended September 30, 2023.
“Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on operational progress for the third quarter and nine months ended September 30, 2023.”
Summit Therapeutics Inc. shareholders approved Approve an amendment to the Plan to increase the number of shares of the Company’s common stock issuable under the Plan by 70,000,000 shares at the 2023-10-12 meeting.
“The Company held a Special Meeting of Stockholders (the “Special Meeting”) on October 12, 2023. The stockholders of the Company of record as of the close of business on September 18, 2023 were asked to vote on an amendment to the Summit Therapeutics Inc. 2020 Stock Incentive Plan (the “Plan”) to increase the number of shares of the Company’s common stock issuable under the Plan by 70,000,000 shares (the “Proposal”). The Proposal was approved at the Special Meeting by the requisite vote of the Company’s stockholders in accordance with the recommendation of the Company’s Board of Directors. Set forth below is the number of votes cast for, against or withheld, as well as the number of abstentions and broker non-votes, as to the Proposal: Proposal For Against Abstain Broker To approve an amendment to the Plan to increase the number of shares of the Company’s common stock issuable under the Plan by 70,000,000 shares. 567,632,197 7,904,039 167,675 —”
Summit Therapeutics Inc. entered into Securities Purchase Agreement with Manmeet S. Soni valued at $5,000,000 (effective 2023-10-13).
“On October 13, 2023, Summit Therapeutics Inc. (the “Company”) entered into a Securities Purchase Agreement with Manmeet S. Soni pursuant to which Mr. Soni is investing $5,000,000 in the Company in exchange for 2,976,190 shares (the “Shares”) of the Company’s common stock (“Common Stock”), at a purchase price of $1.68 per share.”
Manmeet S. Soni was appointed as Chief Operating Officer at Summit Therapeutics Inc..
“On October 13, 2023, the Company appointed Manmeet S. Soni as its Chief Operating Officer.”
Summit Therapeutics Inc. reported the six months ended June 30, 2023 results: net income $557.1 million.
“Net loss for the three and six months ended June 30, 2023 was $14.7 million and $557.1 million, respectively.”
Summit Therapeutics Inc. reported the second quarter ended June 30, 2023 results: net income $14.7 million.
“Net loss for the three and six months ended June 30, 2023 was $14.7 million and $557.1 million, respectively.”
Summit Therapeutics Inc. reported financial results for second quarter 2023.
“On August 2, 2023, Summit Therapeutics Inc. (“Summit” or the “Company”) issued a press release announcing that the Company will host an earnings call to announce its second quarter 2023 financial results and provide an operational update for the Company on Wednesday, August 9, 2023, at 9:00am ET, before the market opens.”
Summit Therapeutics Inc. shareholders approved Advisory vote on compensation of named executive officers at the 2023-05-23 meeting.
“Proposal 3 For Against Abstain Broker Non-Votes Advisory vote on compensation of named executive officers 601,047,918 653,118 472,582 24,127,917”
Summit Therapeutics Inc. shareholders approved Ratification of the appointment of PricewaterhouseCoopers LLP, United States as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-05-23 meeting.
“Proposal 2 For Against Abstain Broker Non-Votes Ratification of the appointment of PricewaterhouseCoopers LLP, United States 626,187,678 24,729 89,128 —”
Summit Therapeutics Inc. shareholders approved Election of Directors at the 2023-05-23 meeting.
“Proposal 1 Election of Directors Director Nominees For Withheld Broker Non-Votes Robert W. Duggan 602,091,126 82,492 24,127,917 Mahkam Zanganeh 602,109,288 64,330 24,127,917 Kenneth A. Clark 602,090,958 82,660 24,127,917 Robert Booth 602,090,089 83,529 24,127,917 Ujwala Mahatme 602,089,139 84,479 24,127,917 Manmeet S. Soni 602,035,379 138,239 24,127,917 Alessandra Cesano 602,081,213 92,405 24,127,917 Yu Xia 602,011,269 162,349 24,127,917”
Summit Therapeutics Inc. reported first quarter ended March 31, 2023 results: net income $542.4 million.
“Net loss for the three months ended March 31, 2023 and 2022 was $542.4 million and $21.4 million, respectively.”
Summit Therapeutics Inc. reported the year ended December 31, 2022 results: net income $78.8 million.
“Net loss for the year ended December 31, 2022 and 2021 was $78.8 million and $88.6 million, respectively.”
Summit Therapeutics Inc. reported the three months ended December 31, 2022 results: net income $19.2 million.
“Net loss for the three months ended December 31, 2022 and 2021 was $19.2 million and $27.1 million, respectively.”
Summit Therapeutics Inc.: Increased authorized shares of common stock from 350,000,000 to 1,000,000,000 (effective 2023-01-19).
“On January 19, 2023, Summit filed Amendment No. 2 to the Restated Certificate of Incorporation (the “Amendment No. 2”) with the Secretary of State of the State of Delaware to increase the number of authorized shares of our common stock by 650,000,000 (from 350,000,000 to 1,000,000,000), which became effective on such date.”
Summit Therapeutics Inc. entered into Promissory Notes with Robert W. Duggan valued at $400 million and $100 million.
“Summit and Mr. Duggan have rectified the Original Notes in order to correctly reflect the parties’ intent in the Original Notes”
Summit Therapeutics Inc. amended Amendment No. 1 to the License Agreement with Akeso, Inc. (effective 2023-01-16).
“Common Stock Issuance Agreement As previously disclosed, on December 5, 2022, we entered into a Collaboration and License Agreement (the “License Agreement”) with Akeso, Inc. and its affiliates (“Akeso”) and certain ancillary transaction documents as set forth in the License Agreement.”
Summit Therapeutics Inc. entered into Common Stock Issuance Agreement with Akeso (effective 2023-01-17).
“Common Stock Issuance Agreement As previously disclosed, on December 5, 2022, we entered into a Collaboration and License Agreement (the “License Agreement”) with Akeso, Inc.”
Summit Therapeutics Inc. entered into Collaboration and License Agreement with Akeso, Inc. and its affiliates valued at $500 million upfront payment (effective 2022-12-05).
“on December 5, 2022, we entered into a Collaboration and License Agreement (the “License Agreement”) with Akeso, Inc. and its affiliates”
Dr. Yu (Michelle) Xia was appointed as member of the Board of Directors at Summit Therapeutics Inc..
“the Board of Directors (the “Board”) of the Company appointed Dr. Yu (Michelle) Xia to serve as a member of the Board pursuant to the terms of the License Agreement.”
Summit Therapeutics Inc. shareholders approved Amendment to Restated Certificate to effect a reverse stock split at a ratio in the range of 1-for-5 to 1-for-10 at the 2023-01-06 meeting.
“Proposal 2 For Against Abstain Broker Amendment No. 2 to Restated Certificate of Incorporation to effect a reverse stock split of the outstanding common stock 186,585,821 3,607,721 28,191 —”
Summit Therapeutics Inc. shareholders approved Amendment to Restated Certificate to increase authorized shares of common stock from 350,000,000 to 1,000,000,000 at the 2023-01-06 meeting.
“Proposal 1 For Against Abstain Broker Amendment No. 2 to Restated Certificate of Incorporation to increase the number of authorizes shares of common stock 188,470,028 1,585,907 165,798 —”
Summit Therapeutics Inc. entered into Collaboration and License Agreement with Akeso, Inc. and its affiliates valued at upfront payment of $500 million (effective 2022-12-05).
“On December 5, 2022, Summit Therapeutics Inc. (the “Company” or “Summit”) entered into a Collaboration and License Agreement (the “License Agreement”) with Akeso, Inc. and its affiliates (“Akeso”) and certain ancillary transaction documents as set forth in the License Agreement.”
Dr. Yu (Michelle) Xia was elected as director at Summit Therapeutics Inc..
“the Board unanimously approved the election of Dr. Yu (Michelle) Xia as a director of the Company, effective upon the Antitrust Clearance Date.”
Dr. Alessandra Cesano was elected as Director at Summit Therapeutics Inc..
“Effective on November 15, 2022, the board of directors (the “Board”) of Summit Therapeutics Inc. (the “Company”) unanimously approved (i) the election of Dr. Alessandra Cesano, MD, PhD as a director of the Company and (ii) the appointment of Dr. Cesano to serve on the Compensation Committee and the Nominating and Corporate Governance Committee of the Board.”
Summit Therapeutics Inc. reported financial results for the third quarter ended September 30, 2022.
“On November 9, 2022, Summit Therapeutics Inc. (the "Company") announced its financial results and operational progress for the third quarter ended September 30, 2022.”
Urte Gayko resigned as Director at Summit Therapeutics Inc..
“effective September 28, 2022, Urte Gayko resigned from the Board of the Company in order to create a vacancy for Dr. Robert Booth, PhD”
Robert Booth was appointed as Director at Summit Therapeutics Inc..
“On September 28, 2022, the Board unanimously approved (i) the election of Dr. Robert Booth, PhD as a director”
Dr. Maky Zanganeh was appointed as Co-Chief Executive Officer and President at Summit Therapeutics Inc..
“Effective July 25, 2022, the board of directors (the “Board”) of Summit Therapeutics Inc. (the “Company”) appointed Dr. Maky Zanganeh to serve as Co-Chief Executive Officer and President of the Company.”
Robert W. Duggan changed role as interim principal financial officer at Summit Therapeutics Inc..
“Mr. Dhingra will replace Robert W. Duggan, who was acting as the Company’s interim principal financial officer since the departure of Michael Donaldson as Chief Financial Officer on July 2, 2021.”
Ankur Dhingra was appointed as Chief Financial Officer at Summit Therapeutics Inc..
“Effective on May 31, 2022, the board of directors (the “Board”) of Summit Therapeutics Inc. (the “Company”) appointed Ankur Dhingra to serve as Chief Financial Officer and Principal Accounting Officer of the Company.”
Jeffrey Maranian resigned as VP Corporate Controller and Principal Accounting Officer at Summit Therapeutics Inc..
“On January 7, 2022, Jeffrey Maranian notified Summit Therapeutics Inc. (the “Company”) that he was resigning from his positions as VP Corporate Controller and Principal Accounting Officer of the Company, effective as of close of business on January 21, 2022.”
Urte Gayko was elected as director at Summit Therapeutics Inc..
“Effective on November 3, 2021, the board of directors (the “Board”) of Summit Therapeutics Inc. (the “Company”) unanimously approved (i) the election of Urte Gayko as a director of the Company, to occupy a newly created seat on the Board and (ii) the appointment of Dr. Gayko to serve on the Nominating and Corporate Governance Committee.”
Ramses Erdtmann resigned as Director at Summit Therapeutics Inc..
“On October 7, 2021, Ramses Erdtmann resigned from the Board to pursue other professional opportunities.”
Kenneth A. Clark was elected as Director at Summit Therapeutics Inc..
“Effective on October 7, 2021, the board of directors (the “Board”) of Summit Therapeutics Inc. (the “Company”) unanimously approved (i) the election of Kenneth A. Clark as a director of the Company and (ii) the appointment of Mr. Clark to serve on each of the Audit, Compensation, and Nominating and Corporate Governance Committees.”
Jeffrey R. Maranian was appointed as principal accounting officer at Summit Therapeutics Inc..
“the board of directors (the “Board”) of the Company appointed Robert W. Duggan to serve as interim principal financial officer and Jeffrey R. Maranian to serve as principal accounting officer.”
Robert W. Duggan was appointed as interim principal financial officer at Summit Therapeutics Inc..
“the board of directors (the “Board”) of the Company appointed Robert W. Duggan to serve as interim principal financial officer and Jeffrey R. Maranian to serve as principal accounting officer.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.